vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Creative Media & Community Trust Corp (CMCT). Click either name above to swap in a different company.

AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $28.5M, roughly 1.6× Creative Media & Community Trust Corp). AbCellera Biologics Inc. runs the higher net margin — -19.9% vs -125.8%, a 105.8% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 3.6%). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -8.5%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Creative Media & Community Trust Corp is a U.S.-headquartered real estate investment trust operating two core segments: it owns, manages and develops creative media facilities including professional film and TV production studios, plus community-focused assets such as affordable housing, neighborhood healthcare centers and local commercial spaces, serving media operators and local communities nationwide.

ABCL vs CMCT — Head-to-Head

Bigger by revenue
ABCL
ABCL
1.6× larger
ABCL
$44.9M
$28.5M
CMCT
Growing faster (revenue YoY)
ABCL
ABCL
+784.8% gap
ABCL
788.4%
3.6%
CMCT
Higher net margin
ABCL
ABCL
105.8% more per $
ABCL
-19.9%
-125.8%
CMCT
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
-8.5%
CMCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
CMCT
CMCT
Revenue
$44.9M
$28.5M
Net Profit
$-8.9M
$-11.4M
Gross Margin
Operating Margin
-63.7%
-125.6%
Net Margin
-19.9%
-125.8%
Revenue YoY
788.4%
3.6%
Net Profit YoY
73.9%
-11.4%
EPS (diluted)
$-0.03
$-3.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
CMCT
CMCT
Q4 25
$44.9M
$28.5M
Q3 25
$9.0M
$26.2M
Q2 25
$17.1M
$29.7M
Q1 25
$4.2M
$32.3M
Q4 24
$5.0M
$27.5M
Q3 24
$6.5M
$28.6M
Q2 24
$7.3M
$34.4M
Q1 24
$10.0M
$34.0M
Net Profit
ABCL
ABCL
CMCT
CMCT
Q4 25
$-8.9M
$-11.4M
Q3 25
$-57.1M
$-12.5M
Q2 25
$-34.7M
$-9.0M
Q1 25
$-45.6M
$-6.1M
Q4 24
$-10.3M
Q3 24
$-51.1M
$-10.4M
Q2 24
$-36.9M
$-796.0K
Q1 24
$-40.6M
$-3.7M
Operating Margin
ABCL
ABCL
CMCT
CMCT
Q4 25
-63.7%
-125.6%
Q3 25
-851.8%
-47.7%
Q2 25
-290.2%
-30.3%
Q1 25
-1479.6%
-19.0%
Q4 24
-128.8%
Q3 24
-1439.4%
-36.9%
Q2 24
-1276.2%
-1.6%
Q1 24
-551.5%
-10.7%
Net Margin
ABCL
ABCL
CMCT
CMCT
Q4 25
-19.9%
-125.8%
Q3 25
-637.8%
-47.5%
Q2 25
-203.3%
-30.3%
Q1 25
-1077.2%
-18.9%
Q4 24
-129.8%
Q3 24
-785.4%
-36.3%
Q2 24
-504.3%
-2.3%
Q1 24
-408.0%
-11.0%
EPS (diluted)
ABCL
ABCL
CMCT
CMCT
Q4 25
$-0.03
$-3.89
Q3 25
$-0.19
$-23.52
Q2 25
$-0.12
$-18.94
Q1 25
$-0.15
$-20.73
Q4 24
$97.71
Q3 24
$-0.17
$-305.04
Q2 24
$-0.13
$-98.64
Q1 24
$-0.14
$-125.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
CMCT
CMCT
Cash + ST InvestmentsLiquidity on hand
$128.5M
$15.4M
Total DebtLower is stronger
$509.8M
Stockholders' EquityBook value
$966.9M
$265.4M
Total Assets
$1.4B
$859.2M
Debt / EquityLower = less leverage
1.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
CMCT
CMCT
Q4 25
$128.5M
$15.4M
Q3 25
$83.2M
$17.3M
Q2 25
$92.4M
$27.8M
Q1 25
$159.3M
$19.8M
Q4 24
$156.3M
$20.3M
Q3 24
$126.6M
$18.5M
Q2 24
$148.3M
$29.3M
Q1 24
$123.6M
$21.3M
Total Debt
ABCL
ABCL
CMCT
CMCT
Q4 25
$509.8M
Q3 25
$527.8M
Q2 25
$535.6M
Q1 25
$512.7M
Q4 24
$505.7M
Q3 24
$478.3M
Q2 24
$485.1M
Q1 24
$472.8M
Stockholders' Equity
ABCL
ABCL
CMCT
CMCT
Q4 25
$966.9M
$265.4M
Q3 25
$964.0M
$281.9M
Q2 25
$1.0B
$287.1M
Q1 25
$1.0B
$293.0M
Q4 24
$1.1B
$304.5M
Q3 24
$1.1B
$321.0M
Q2 24
$1.1B
$351.1M
Q1 24
$1.1B
$369.9M
Total Assets
ABCL
ABCL
CMCT
CMCT
Q4 25
$1.4B
$859.2M
Q3 25
$1.4B
$871.8M
Q2 25
$1.4B
$885.0M
Q1 25
$1.3B
$882.3M
Q4 24
$1.4B
$889.6M
Q3 24
$1.4B
$868.0M
Q2 24
$1.4B
$891.2M
Q1 24
$1.5B
$887.5M
Debt / Equity
ABCL
ABCL
CMCT
CMCT
Q4 25
1.92×
Q3 25
1.87×
Q2 25
1.87×
Q1 25
1.75×
Q4 24
1.66×
Q3 24
1.49×
Q2 24
1.38×
Q1 24
1.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
CMCT
CMCT
Operating Cash FlowLast quarter
$-34.7M
$5.8M
Free Cash FlowOCF − Capex
$-44.6M
FCF MarginFCF / Revenue
-99.4%
Capex IntensityCapex / Revenue
21.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
CMCT
CMCT
Q4 25
$-34.7M
$5.8M
Q3 25
$-52.6M
$3.7M
Q2 25
$-32.4M
$-2.5M
Q1 25
$-11.6M
$1.2M
Q4 24
$-108.6M
$17.0M
Q3 24
$-28.9M
$10.3M
Q2 24
$-30.0M
$3.9M
Q1 24
$-41.7M
$1.6M
Free Cash Flow
ABCL
ABCL
CMCT
CMCT
Q4 25
$-44.6M
Q3 25
$-61.5M
Q2 25
$-45.8M
Q1 25
$-22.2M
Q4 24
$-187.0M
Q3 24
$-47.4M
Q2 24
$-50.1M
Q1 24
$-65.8M
FCF Margin
ABCL
ABCL
CMCT
CMCT
Q4 25
-99.4%
Q3 25
-687.0%
Q2 25
-267.9%
Q1 25
-524.0%
Q4 24
-3702.8%
Q3 24
-728.4%
Q2 24
-683.8%
Q1 24
-661.5%
Capex Intensity
ABCL
ABCL
CMCT
CMCT
Q4 25
21.9%
Q3 25
99.7%
Q2 25
78.2%
Q1 25
251.1%
Q4 24
1552.7%
Q3 24
284.6%
Q2 24
274.6%
Q1 24
242.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons